In Q3, West delivered impressive growth across all market units and geographies, with 27.9% organic sales growth and a 530 basis point expansion in gross profit margin. High-value products accounted for 73% of proprietary product sales and grew double-digits. The company is raising its full-year sales guidance to $2.80-$2.81 billion and adjusted-diluted earnings per share guidance to $8.40-$8.50 due to continued strong performance. Despite supply chain challenges, West is investing in capacity expansion, including NovaPure production, to meet demand. The company's momentum is supported by a robust committed order book, positioning it well for sustained growth in 2022 and beyond.